Table 2 Characteristics of patients.

From: Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions

Variable

csPCa (n = 28)

Non-csPCa (n = 126)

P

Overall

Age (years, mean ± SD)

74.0 ± 6.3

69.1 ± 8.1

0.003

69.9 ± 8.0

PSA (ng/ml/ml, median [IQR])

10.79 (7.90-25.54)

10.79 (7.92–15.89)

0.64

10.79 (7.92–16.25)

PSAD (ng/ml/ml, median [IQR])

0.155 (0.119–0.254)

0.124 (0.087–0.197)

0.02

0.13 (0.093–0.209)

PV (ml, median [IQR])

72.58 (49.72-113.74)

89.04 (66.96-126.72)

0.04

87.74 (64.15–122.8)

TZV (ml, median [IQR])

43.99 (24.48–82.89)

63.93 (44.85-101.43)

0.01

61.02 (41.4-98.86)

TZPSAD (ng/ml/ml, median [IQR])

0.327 (0.211–0.510)

0.175 (0.117–0.273)

< 0.001

0.194 (0.124–0.310)

TZ-ratio (mean ± SD)

0.58 ± 0.18

0.73 ± 0.15

< 0.001

0.70 ± 0.17

  1. csPCa, clinically significant prostate cancer; IQR, interquartile range; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; PV, prostate volume; SD, standard deviation; TZPSAD, transitional zone prostate-specific antigen density; TZ-ratio, transitional zone volume ratio; TZV, transitional zone volume.
Back to article page